ADAMTS13 and thrombotic thrombocytopenic purpura: Many studies have shown that TMA patients without ADAMTS‐13 deficiency have significantly higher median creatinine levels and platelet counts at presentation than those with confirmed acquired TTP 9, 33, 34.